{"id":"NCT03353350","sponsor":"Hanmi Pharmaceutical Company Limited","briefTitle":"Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise","officialTitle":"A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-05","primaryCompletion":"2020-01-29","completion":"2020-09-07","firstPosted":"2017-11-27","resultsPosted":"2022-01-18","lastUpdate":"2022-01-18"},"enrollment":406,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"efpeglenatide (SAR439977)","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Efpeglenatide 2mg","type":"EXPERIMENTAL"},{"label":"Efpeglenatide 4 mg","type":"EXPERIMENTAL"},{"label":"Efpeglenatide 6 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with T2DM (Type 2 Diabetes Mellitus) inadequately controlled with diet and exercise.\n\nSecondary Objectives:\n\n* To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison to placebo on glycemic control\n* To demonstrate the superiority of once-weekly injection of efpeglenatide in comparison to placebo on body weight\n* To evaluate the safety of once-weekly injection of efpeglenatide","primaryOutcome":{"measure":"Change in Glycated Hemoglobin (HbA1c) (%)","timeFrame":"Baseline to Week 30","effectByArm":[{"arm":"Placebo","deltaMin":-0.46,"sd":1.16},{"arm":"Efpeglenatide 2 mg","deltaMin":-1.14,"sd":0.96},{"arm":"Efpeglenatide 4 mg","deltaMin":-1.48,"sd":1.01},{"arm":"Efpeglenatide 6 mg","deltaMin":-1.59,"sd":1.04}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":54,"countries":["United States","Germany","Poland","Ukraine","United Kingdom"]},"refs":{"pmids":["35671039"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":102},"commonTop":["Diarrhoea","Nausea","Constipation","Headache","Injection site pain"]}}